Functional models of Parkinson's disease: a valuable tool in the development of novel therapies.
about
Mesenchymal stem cells for the treatment of neurodegenerative and psychiatric disordersPreservation of function in Parkinson's disease: what's learning got to do with it?Early Parkinson's disease symptoms in α-synuclein transgenic monkeys.Multimodal MRI Evaluation of the MitoPark Mouse Model of Parkinson's DiseaseEvolution of extra-nigral damage predicts behavioural deficits in a rat proteasome inhibitor model of Parkinson's diseaseGlutathione depletion and overproduction both initiate degeneration of nigral dopaminergic neuronsImprovement of the Rett syndrome phenotype in a MeCP2 mouse model upon treatment with levodopa and a dopa-decarboxylase inhibitorNigral proteasome inhibition in mice leads to motor and non-motor deficits and increased expression of Ser129 phosphorylated α-synucleinConnectivity Changes in Parkinson's Disease.Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease.Behavioral phenotyping of mouse models of Parkinson's disease.Role for the nicotinic cholinergic system in movement disorders; therapeutic implications.Nicotine as a potential neuroprotective agent for Parkinson's disease.Mesenchymal stem cells for the treatment of neurodegenerative disease.Origins and suppression of oscillations in a computational model of Parkinson's diseaseManganese-Induced Parkinsonism due to Ephedrone AbuseFocus on α4β2* and α6β2* nAChRs for Parkinson's Disease Therapeutics.α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.Animal models of the non-motor features of Parkinson's disease.Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson's disease using in vivo 18F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging.Age-dependent α-synuclein aggregation in the Microcebus murinus lemur primateP73 and age-related diseases: is there any link with Parkinson Disease?Ganoderma Lucidum polysaccharides protect against MPP(+) and rotenone-induced apoptosis in primary dopaminergic cell cultures through inhibiting oxidative stress.Understanding the molecular basis of Parkinson's disease, identification of biomarkers and routes to therapy.Bringing natural products into the fold - exploring the therapeutic lead potential of secondary metabolites for the treatment of protein-misfolding-related neurodegenerative diseases.Models of α-synuclein aggregation in Parkinson's disease.Non-human primate models of PD to test novel therapies.Biomarker Research in Parkinson's Disease Using Metabolite Profiling.The phosphodiesterase inhibitor, ibudilast, attenuates neuroinflammation in the MPTP model of Parkinson's disease.Magnolol Protects against MPTP/MPP(+)-Induced Toxicity via Inhibition of Oxidative Stress in In Vivo and In Vitro Models of Parkinson's Disease.Neuroprotective Surgical Strategies in Parkinson's Disease: Role of Preclinical Data.An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition.Vanillin Attenuated Behavioural Impairments, Neurochemical Deficts, Oxidative Stress and Apoptosis Against Rotenone Induced Rat Model of Parkinson's Disease.Differential α-synuclein expression contributes to selective vulnerability of hippocampal neuron subpopulations to fibril-induced toxicity.
P2860
Q26801575-71910498-FD5C-482F-8FA4-415BE6E3F304Q26853387-6352710D-9D3F-4036-806A-C775F82E6C98Q27301058-0DB464EC-602A-46DC-BB38-DC94B9282652Q27316725-8F9EE52B-CBC4-49C4-8A48-626229F24A4EQ27350440-A485EA5A-595D-489C-BBCD-232B6F296800Q30498761-012264B0-DD0B-45D6-9209-AFE04105F739Q30593615-4AAEC9B9-E28C-4873-AB50-24F375E849D6Q30633819-01A94162-A71D-468C-B641-1A08A005E099Q33363796-0A9E7F61-7647-490B-89CE-0FBF6DEAEFEFQ33522039-38B85541-E277-4AD0-A24E-F263DDF0E541Q33820609-899726AB-5B19-43BB-9D55-8A4353777794Q34112026-9254272A-1C2C-402C-A1B2-409CCC62066CQ34281003-9C1FF15A-5FB2-4439-AE4E-20113B68A169Q34473474-B8E7F4AC-C7D8-4DB2-BBB7-F4E3C4384E88Q34476239-CE50B949-5E5E-4E2F-9804-4EE60628CF50Q34595356-145FC6F1-204A-4FBC-8752-598FFAFB2403Q34793270-6052FBB8-27C7-42A8-8035-276B162094AAQ35264378-7484B367-BE53-4FE7-8B69-03637A0C3DF4Q35589979-578CBE32-38D2-456D-8A74-A47D6E2DD48DQ36235578-11B658C2-B62A-40CC-AD5A-E7D969F82F87Q36296658-B5378FB9-734E-49FF-AF7D-FFB140040A6DQ36435001-CBEB496D-A2DC-4D32-A4C4-4EDA7A746420Q36736367-581CF056-9902-4BF4-A546-93D8AD1E5B06Q37019188-CDC0BA3A-3D99-4806-958A-DFB5397E177BQ37775037-13E4E474-79DC-49B0-A445-7576240A4513Q37798463-EAEA6D4A-CE47-458C-8DBB-59D3A8E93314Q38286574-5C161E17-66F6-4E7D-9347-192C0D03EBA3Q39229450-B8E8C709-D324-4184-AF4B-4430E06F6E36Q41666702-71721D19-3225-4211-BB40-77620D586FEBQ41913461-72860AF6-3DD5-4E24-A599-4BE3AF6FE467Q42175955-206A8484-A8F4-4721-B612-A4B2EA1DB30FQ44266420-A3204DE1-BB07-4341-BCE3-53FA65770BF3Q48171351-B751A289-50CC-4AA6-96AC-C69B53141073Q50523809-A1C6E72E-27F3-4884-9A2B-407E837366A7Q51744776-2CAE5671-9648-4CE5-9093-56F306680EA1
P2860
Functional models of Parkinson's disease: a valuable tool in the development of novel therapies.
description
2008 nî lūn-bûn
@nan
2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Functional models of Parkinson ...... evelopment of novel therapies.
@ast
Functional models of Parkinson ...... evelopment of novel therapies.
@en
Functional models of Parkinson ...... evelopment of novel therapies.
@nl
type
label
Functional models of Parkinson ...... evelopment of novel therapies.
@ast
Functional models of Parkinson ...... evelopment of novel therapies.
@en
Functional models of Parkinson ...... evelopment of novel therapies.
@nl
prefLabel
Functional models of Parkinson ...... evelopment of novel therapies.
@ast
Functional models of Parkinson ...... evelopment of novel therapies.
@en
Functional models of Parkinson ...... evelopment of novel therapies.
@nl
P2860
P356
P1433
P1476
Functional models of Parkinson ...... evelopment of novel therapies.
@en
P2093
Peter Jenner
P2860
P304
P356
10.1002/ANA.21489
P478
64 Suppl 2
P577
2008-12-01T00:00:00Z